Citius Pharmaceuticals (CTXR) Gross Margin (2025 - 2026)

Citius Pharmaceuticals' (CTXR) quarterly Gross Margin came in at 67.07% in Q2 2026, down 16.44% quarter-over-quarter from 80.27% in Q1 2026.

Analysis

Citius Pharmaceuticals (CTXR) Gross Margin (2025 - 2026) Analysis & Trends

Citius Pharmaceuticals (CTXR) has reported Gross Margin for 2 consecutive years, with 67.07% the latest figure, recorded in Q2 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Johnson & Johnson	641.86 Bn	621.10 Bn	17.26 Bn	68.19%
2	AbbVie	446.73 Bn	440.17 Bn	12.70 Bn	74.74%
3	Merck	357.89 Bn	350.75 Bn	12.21 Bn	73.54%
4	Novartis Ag	267.68 Bn	259.99 Bn	11.24 Bn	78.02%
5	Pfizer	156.81 Bn	145.11 Bn	10.94 Bn	72.78%
6	Sanofi	52.21 Bn	44.83 Bn	10.79 Bn	80.05%
7	Revolution Medicines	43.14 Bn	43.14 Bn	-	-
8	Incyte	24.64 Bn	20.11 Bn	1.57 Bn	93.73%
9	United Therapeutics	21.29 Bn	18.63 Bn	683.80 Mn	87.30%
10	Citius Pharmaceuticals	15.53 Mn	15.53 Mn	1.00 Mn	67.07%

Historic Data

Download Data